Alex Tsankov, PhD

Lung adenocarcinoma (LUAD) with TP53 mutations is an aggressive cancer that suppresses the immune system. Approximately half of LUAD cases have TP53 mutations, where to date no targeted therapies exist for this mutation, resulting in poor outcomes. Our proposed research explores how TP53 mutations alter immunosuppressive interactions between cancer and immune cells involving the proteins PVR and TIGIT. Using emerging spatial transcriptomics technologies, we will map where these interactions occur within tumor tissues, providing novel spatial and cellular context. We will also test new treatment strategies by disrupting PVR-TIGIT interactions in combination with other existing immunotherapies. Additionally, we will assess the therapeutic potential of these new combination treatments using in-vitro models that mimic patient tumors. By combining cutting-edge spatial technologies and in vitro culture modeling, this study aims to identify new treatment strategies for patients with TP53-mutant LUAD and promises to ultimately improve outcomes and personalize care for these patients.

American Lung Association Susan Rappaport Lung Cancer Discovery Award